Back

Hyperlipoproteinemia(a) in coronary artery disease patients: who are patients with very high levels and how do they respond to the PCSK9 antibody therapy?

26 August 2023 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Risk factors and prevention: lipids (2) Lipids ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Marko Novakovic

University Medical Centre Ljubljana, Ljubljana (Slovenia)

8 More presentations in this session

Presentation thumbnail
Prevalence and outcomes of familial hypercholesterolemia in young patients undergoing coronary bypass surgery
Doctor J. Black (Hobart, AU)
Abstract Slides Video
Presentation thumbnail
Increased triglyceride independently associates with premature structural and functional cardiac damage progression in asymptomatic adolescents: a 7-year longitudinal study
Doctor A. Agbaje (Kuopio, FI)
Abstract Slides Video
Presentation thumbnail
Characterization of lipidic coronary atheroma under control of low-density lipoprotein <1.8 mmol/l and lipoprotein (a) <50 mg/dl in patients with coronary artery disease
Doctor D. Shishikura (Takatsuki, JP)
Abstract Slides Video
Presentation thumbnail
Increased Lipoprotein (a) and familial hypercholesterolemia: a dangerous combination.Data from a 12-year follow-up study
Doctor I. Andrikou (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Analysis of routine molecular genetic diagnostics of familial hypercholesterolemia at tertiary care lipid clinics
Doctor M. Ferch (Vienna, AT)
Abstract Slides Video

Access the full session

Session thumbnail
Risk factors and prevention: lipids (2)

The Event

Event poster

ESC Congress 2023

26 August 2023 12:15 CET
You may be interested in
thumbnail
Congress Presentation
The association of lipoprotein(a) with patient characteristics and mortality in a primary prevention cohort: data from our clinic database
thumbnail
Congress Presentation
What is new regarding lipoprotein(a)
thumbnail
Congress Presentation
The impact of very highly elevated lipoprotein(a) levels on the early onset, complexity, and extent of coronary artery disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources